Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer

MLA

Erika Hamilton, et al. “Phase 1b Study of H3B-6545 in Combination with Palbociclib in Women with Metastatic Estrogen Receptor–positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.” Journal of Clinical Oncology, vol. 39, May 2021, p. e13025. EBSCOhost, https://doi.org/10.1200/jco.2021.39.15_suppl.e13025.

APA

Erika Hamilton, Manav Korpal, Jianjun Alan Xiao, Stephen R. D. Johnston, Timothy J. Pluard, J. Marc Pipas, Judy Sing-Zan Wang, Dejan Juric, Elizabeth Hnitecki, Lihua Yu, Catherine Rose Scholz, Lisa Cantagallo, Tarek Sahmoud, Benoit Destenaves, Lei Gao, Antonio Gualberto, & Zhaojie Zhang. (2021). Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Journal of Clinical Oncology, 39, e13025. https://doi.org/10.1200/jco.2021.39.15_suppl.e13025

Chicago

Erika Hamilton, Manav Korpal, Jianjun Alan Xiao, Stephen R. D. Johnston, Timothy J. Pluard, J. Marc Pipas, Judy Sing-Zan Wang, et al. 2021. “Phase 1b Study of H3B-6545 in Combination with Palbociclib in Women with Metastatic Estrogen Receptor–positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.” Journal of Clinical Oncology 39 (May): e13025. doi:10.1200/jco.2021.39.15_suppl.e13025.